Who was studied, and how
Two numbers in the abstract
Where each one falls
Where it lands on the map
4,974people with dyslipidemia, in this paper
The trial randomly assignedassigned by chance
alirocumab
control (placebo/ezetimibe)
Lowered major heart events−24%
randomisedthe abstract, start to end
… to be 24% lower (adjusted hazard ratio, 0.76; 95% confidence interval, …
… with MACE rates (hazard ratio, 0.71; 95% confidence interval, …
← favours treatmentfavours comparator →
could be chanceMACE (coronary heart disease death, nonfatal myocardial infarction, ischemic stroke, or unstable angina requiring hospitalization)alirocumab vs control (placebo/ezetimibe)
HR 0.760.63–0.91
MACE (coronary heart disease death, nonfatal myocardial infarction, ischemic stroke, or unstable angina requiring hospitalization)alirocumab vs control (placebo/ezetimibe)
HR 0.710.57–0.89
PCSK9 inhibitorsCardiovascular events
1 / 4